Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
F. Cardoso, A. Di Leo,+, C. Lohrisch, C. Bernard, F. Ferreira and M. J. Piccart
Department of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
‘It matters not how long we live, but how.’
Festus, Philip James Bailey
Despite almost 30 years of clinical cancer research, the true impact of second and subsequent lines of chemotherapy on the outcome of metastatic breast cancer patients, especially on the duration of survival, is still unknown.
In the virtually incurable metastatic setting, issues like quality of life and patients’ preferences gain particular relevance. At the turn of the century, in-depth rethinking of the design of clinical trials run in this challenging disease setting appears to be warranted.
Annals of Oncology 13:197-207, 2002
© 2002 European Society for Medical Oncology
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.